Shuttle Pharmaceuticals

Historical price data

Shuttle Pharmaceuticals is a clinical-stage biotech focused on enhancing radiation therapy (RT) for cancer through novel small molecule therapies. Its mission is to increase cure rates and improve quality of life by developing targeted radiation sensitizers and protective agents. The company's strategy leverages a dual-platform approach of halogenated pyrimidines and selective HDAC inhibitors, with a lead Phase II candidate, Ropidoxuridine, in glioblastoma. Shuttle is advancing its pipeline through strategic academic collaborations and recently announced initiatives in AI for scientific workflows.

A dual-platform approach featuring halogenated pyrimidine radiation sensitizers (e.g., Ropidoxuridine) and a proprietary portfolio of selective histone deacetylase (HDAC) inhibitors designed to radiosensitize tumors, protect normal tissue, and modulate immune response.

Competes against off-label chemotherapies and other biotechs developing novel radiosensitizers. Differentiation hinges on its specialized platform, HDAC inhibitor IP, and potential for a superior therapeutic index. Must demonstrate clear efficacy/safety advantages to displace entrenched, low-cost standards of care.